Document is current
Any future updates will be listed below
-
Authors
Bai, Jiangtao
Asakawa, Tetsuya https://orcid.org/0000-0002-2300-3509
Yuan, Wenfang
Lin, Yuanlong
Ju, Hao
Xu, Dandan
Yang, Mingming
Li, Shuo
Li, Guanguan
Guo, Deyin
Lu, Hongzhou
Zhang, Xumu
-
Funding
Funding for this research was provided by:
the Shenzhen Clinical Research Center for Emerging Infectious Diseases (LCYSSQ20220823091203007)
Shenzhen High-level Hospital Construction Fund (23274G1001)
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 13 January 2025
First Online: 25 January 2025
Declarations
:
: This study was approved and supervised by the Ethical Committee of Shenzhen Third People’s Hospital (approval No: 2022-009), the Ethical Committee of Guangdong Second Provincial General Hospital (approval no: 2022-YWLCYJ-017-02), the Ethical Committee of Shijiazhuang Fifth Hospital (approval no: 2022-YW-004-1), and the Ethical Committee of People’s Hospital of Longhua Shenzhen (approval no: 2022-003Y-02PJ). All interventions were conducted in strict compliance with the protocol and the Declaration of Helsinki (2013). Signed informed consent was obtained from all participants before enrollment.
: Not application.
: ClinicalTrials.gov ID: NCT05676073, , Registration Date: 2023-01-03.
: JB, DX, and MY are employees of Shenzhen Kexing Pharmaceutical Co., Ltd, the other authors declare no competing interests.
